Highest-materiality recent filing
Biomerica sells Diagnosis stake for $500k to CEO-affiliated buyers; note forgivable on transfer
Biomerica sells its 6% stake in Diagnosis S.A. (78,750 shares) to CEO-affiliated entities for $500,000.
All five director nominees elected with majority votes: Irani, Barbieri, Bing Chin, Huff, Moatazedi.
Gary Huff appointed as independent director effective Oct 7, 2025; will serve on Audit, Comp, and Governance committees.
Biomerica appoints Eric Chin to board; Cathy Coste resigns effective June 4
Cathy Coste resigned as director effective June 4, 2025; no disagreement with the company.
Biomerica implements 1-for-8 reverse stock split to regain Nasdaq compliance
Reverse split ratio of 1-for-8 reduces shares outstanding from ~20.4M to ~2.5M.
Biomerica shareholders approve reverse stock split authorization and 2024 Stock Incentive Plan
All five director nominees elected with overwhelming support; broker non-votes 5.5M.
Biomerica gets Nasdaq extension until May 5, 2025 to regain $1 bid price compliance
Received Nasdaq extension on Nov 5, 2024; new compliance deadline is May 5, 2025.
Biomerica Chairman Jack Kenny resigns from board effective June 26, 2024
Jack Kenny resigned as board member and Chairman, effective June 26, 2024.
Biomerica receives Nasdaq bid price deficiency notice; enters $5.5M at-market stock offering
Nasdaq notified Biomerica on May 7, 2024 that bid price was below $1.00 for 32 consecutive business days, violating Listing Rule 5550(a)(2).
Biomerica reports voting results from 2023 annual meeting
Stockholders elected six director nominees: Zackary Irani (5,973,554 for), Allen Barbieri, Jane Emerson, Catherine Coste, David Moatazedi, Jack Kenny.
Biomerica submits final H. pylori dataset to FDA for 510(k) review of hp+detect test
Submitted final H. pylori data-set to FDA on Sep 15, 2023, as requested during FDA's 510(k) review.
Biomerica appoints former Meridian CEO Jack Kenny to Board of Directors
Appointment effective August 25, 2023; Board expanded to add independent director.
Biomerica amends bylaws to change voting standard to limit broker non-vote effect
Board approved bylaw amendment on July 24, 2023, effective immediately.
Biomerica discloses partnership with Gastro Health; no financial terms given
New relationship with Gastro Health, a group of over 390 physicians and 100+ care centers across seven states.
Biomerica closes $8M public offering of 3.33M shares at $2.40/share
Raised $8M gross, ~$7.4M net from 3,333,333 shares at $2.40/share via Craig-Hallum.
Biomerica appoints Gary Lu as CFO effective March 1, 2023
Gary Lu, 42, previously Controller/VP Finance at Happy Money (Sep 2019-Feb 2023).
Biomerica presents investor presentation; no specific material facts from provided exhibit text
On February 6, 2023, Biomerica delivered an investor presentation to the investment community.
Biomerica corrects 8-K: 2022 Stock Incentive Plan not approved at annual meeting
Proposal 5 (2022 Stock Incentive Plan) failed under correct majority-of-outstanding-shares standard; 2,395,243 for, 2,227,813 against, 2,475,235 broker non-votes.
Biomerica CFO Steve Sloan resigns; stays interim while search underway
CFO Steve Sloan notified resignation on Dec 12, 2022 to pursue new career opportunity.
Biomerica amends incentive plan to require stockholder vote for option repricing or buyouts
Board unanimously approved amendments removing ability to reprice or buy out options without stockholder approval.
Director Mark Sirgo steps down; David Moatazedi elected to Biomerica board
Mark Sirgo left the Board of Directors on December 7, 2022 at the annual shareholder meeting.
Biomerica shareholders elect all five director nominees; approve 2022 Stock Incentive Plan
Zackary Irani elected with 4,584,648 votes; all nominees received majority of votes cast.
Biomerica posts updated investor presentation; no specific material changes disclosed
Investor presentation posted on company website; no financial or operational details provided in the 8-K.
Biomerica dismisses PKF San Diego as auditor, engages Haskell & White
Audit committee dismissed PKF San Diego effective April 19, 2022.
Subject Global Assessment of Relief (SGA) endpoint achieved p=0.007 for all IBS subtypes at 8 weeks.
Biomerica preliminary Q2 revenue $4.6M (+238% YoY); backlog $4M; InFoods trial data due Jan 2022
Revenue approximately $4.6M for Q2 ended Nov 30, 2021, up 238% from $1.4M a year ago, driven by COVID test demand.
All five nominees (Zackary Irani, Catherine Coste, Allen Barbieri, Jane Emerson, Mark Sirgo) elected with ~4.86M-4.87M votes for each.
SEC concludes investigations into Biomerica and CEO with no enforcement action
SEC notified Biomerica on Dec 2, 2021 that subpoena investigations from July & Dec 2020 are closed with no enforcement action.
Biomerica restates FY2021 & earlier results due to stock-based compensation accounting errors
Non-cash stock-based compensation was understated; expensed on vesting dates instead of ratably over vesting period, with incorrect forfeiture estimates.
On the same date, the Board appointed Mr. Eric Chin to serve as an independent member of the Board, effective immediately
Effective June 4, 2025, Ms. Cathy Coste stepped down as a member of the Board of Directors
On June 26, 2024, Mr. Jack Kenny notified Biomerica, Inc. (the "Company") of his resignation as a member of the board of directors of the Company (the "Board") and all committees thereof, and as the Company’s Chairman of the Board, effective immediately.
Effective August 25, 2023, the board of directors (the “Board”) of Biomerica, Inc. (the “Company”) expanded the size of the Board by one member and elected and appointed Mr. Jack Kenny to serve as an independent member of the Board effective immediately.
Effective March 1, 2023, the Board of Directors of Biomerica, Inc. (the “Company”) appointed Gary Lu as its Chief Financial Officer, principal financial officer and principal accounting officer.
In connection with Mr. Lu’s appointment as Chief Financial Officer, Steve Sloan, the Company’s former Chief Financial Officer and current interim Chief Financial Officer, stepped down as interim Chief Financial Officer, effective as of March 1, 2023.
On December 12, 2022, Steve Sloan notified Biomerica Inc. (the “Company”) that he will be stepping down from his position as Chief Financial Officer (“CFO”) of the Company.
At the Annual Shareholder Meeting, shareholders elected Mr. David Moatazedi to fill the seat vacated by Mr. Sirgo.
On December 7, 2022, at the Company’s Annual Shareholder Meeting, Mr. Mark Sirgo stepped down as a member of the Board of Directors of Biomerica.
Max materiality 0.80 · Median 0.50 · Most common event other_material